Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial
In brief
Semaglutide normalizes heart filling pressures in 54% of patients with obesity and HFpEF
In this 81-patient randomized trial, weekly semaglutide lowered exercise-related heart filling pressure by about 11 mmHg more than placebo after 52 weeks; 54% of treated patients met the study's definition of hemodynamic remission, versus 7% on placebo. The findings offer a possible explanation for symptom benefits, but the small trial does not establish how these pressure changes affect longer-term clinical outcomes.
- Journal
- Nature medicine (Q1)
- Published
- 8 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Barry A Borlaug, Michael D Jensen, Milton Packer, Yogesh N V Reddy, Tomonari Harada, Fahime Ghanbari, et al.
- PMID
- 43000472
- DOI
- 10.1038/s41591-026-04762-3
Why clinicians should know about it
- Picked for Cardiology and Cardiovascular Medicine (top studies of the week, 15 November 2026): Randomized trial shows semaglutide lowers filling pressures in obese HFpEF
Abstract
The glucagon-like peptide-1 receptor agonist semaglutide improves symptoms in heart failure with preserved ejection fraction (HFpEF) through unclear mechanisms. Here, in this double-blind, placebo-controlled trial, we randomly assigned 81 patients (47 women) with HFpEF and obesity to semaglutide (2.4 mg weekly) or placebo for 52 weeks. The primary outcome was the change in invasively measured pulmonary artery wedge pressure (PAWP), a direct measure of cardiac congestion, during low-intensity exercise. Additional mechanistic outcomes included other hemodynamic measures and hemodynamic HFpEF remission (defined as normal PAWP under conditions of both rest and exercise at 52 weeks). At baseline, PAWP was 17.5 ± 4.3 mmHg at rest and 31.7 ± 5.2 mmHg during exercise. After 52 weeks, the mean change in PAWP during exercise was -9.8 (95% confidence interval (CI): -11.3 to -8.2) mmHg with semaglutide and +0.9 (95% CI: -1.3 to 3.0) mmHg with placebo (estimated difference, -10.6 mmHg; 95% CI: -13.3 to -8.0; P < 0.0001). As compared to placebo, semaglutide also decreased resting PAWP (estimated difference, -7.1 mmHg; 95% CI: -9.8 to -4.4; P < 0.0001), and semaglutide-treated patients were more likely to experience hemodynamic remission (53.7% versus 7.4%, odds ratio = 14.1, 95% CI: 3.0-134.6, P < 0.001). The results from this trial indicate that, in patients with HFpEF and obesity, treatment with semaglutide reduced left heart filling pressures during exercise and at rest and was associated with hemodynamic HFpEF remission in over half of treated patients. ClinicalTrials.gov identifier: NCT05371496 .
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.